Objective response rates assessed by CA score (all patients). MF (mycosis fungoides): 280 mg encompasses both early-stage (n = 11) and advanced-stage (n = 9), 560 mg encompasses early-stage (n = 14), and 980 mg encompasses advanced-stage patients (n = 4); SS (Sézary syndrome): all advanced stage.